AbCellera Biologics Inc [ABCL] stock prices are down -1.37% to $3.61 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ABCL shares have lost -9.07% over the last week, with a monthly amount drifted -35.30%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
AbCellera Biologics Inc [NASDAQ: ABCL] stock has seen the most recent analyst activity on November 07, 2025, when Leerink Partners downgraded its rating to a Market Perform but kept the price target unchanged to $4 for it. On August 20, 2024, downgrade downgraded it’s rating to Hold. The Benchmark Company upgraded its rating to a Buy but stick to its price target of $9 on February 22, 2024. KeyBanc Capital Markets initiated its recommendation with a Overweight and recommended $6 as its price target on December 05, 2023. The Benchmark Company downgraded its rating to Hold for this stock on November 06, 2023.
The stock price of AbCellera Biologics Inc [ABCL] has been fluctuating between $1.89 and $6.51 over the past year. Currently, Wall Street analysts expect the stock to reach $20.17 within the next 12 months. AbCellera Biologics Inc [NASDAQ: ABCL] shares were valued at $3.61 at the most recent close of the market. An investor can expect a potential return of 458.73% based on the average ABCL price forecast.
Analyzing the ABCL fundamentals
The AbCellera Biologics Inc [NASDAQ:ABCL] reported sales of 35.32M for trailing twelve months, representing a surge of 37.62%. Gross Profit Margin for this corporation currently stands at -1.05% with Operating Profit Margin at -8.6%, Pretax Profit Margin comes in at -5.8%, and Net Profit Margin reading is -4.86%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.17 and Total Capital is -0.51. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.52 points at the first support level, and at 3.43 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.75, and for the 2nd resistance point, it is at 3.90.
Ratios To Look Out For
It’s worth pointing out that AbCellera Biologics Inc [NASDAQ:ABCL]’s Current Ratio is 10.10. As well, the Quick Ratio is 10.10, while the Cash Ratio is 1.21. Considering the valuation of this stock, the price to sales ratio is 30.59, the price to book ratio is 1.12.
